Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Japanese Journal of Clinical Oncology|May 16, 2019
The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancerHiromi Watanabe, Toshio Kubo, Kiichiro Ninomiya, et al.
Japanese Journal of Clinical Oncology|September 2, 2020
Immune checkpoint inhibitor efficacy and safety in older non-small cell lung cancer patientsToshio Kubo, Hiromi Watanabe, Kiichiro Ninomiya, et al.
Asia-Pacific Journal of Clinical Oncology|April 3, 2019
A phase I/II trial of weekly nab-paclitaxel for pretreated non-small-cell lung cancer patients without epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangementDaijiro Harada, Toshiyuki Kozuki, Naoyuki Nogami, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 2, 2021
A randomized trial of sodium alginate prevention of esophagitis in LA-NSCLC receiving chemoradiotherapy: OLCSG1401Kiichiro Ninomiya, Toshihide Yokoyama, Katsuyuki Hotta, et al.
Lung Cancer (Amsterdam, Netherlands)|August 31, 2023
A randomized phase II study of afatinib alone or combined with bevacizumab for treating chemo-naïve patients with non-small cell lung cancer harboring EGFR mutationsTakashi Ninomiya, Nobuhisa Ishikawa, Toshiyuki Kozuki, et al.
European Journal of Cancer (Oxford, England : 1990)|August 31, 2014
A phase II study of S-1 chemotherapy with concurrent thoracic radiotherapy in elderly patients with locally advanced non-small-cell lung cancer: the Okayama Lung Cancer Study Group Trial 0801Keisuke Aoe, Nagio Takigawa, Katsuyuki Hotta, et al.
Clinical Lung Cancer|December 6, 2018
Phase 2 Study of Afatinib Alone or Combined With Bevacizumab in Chemonaive Patients With Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations: AfaBev-CS Study ProtocolTakashi Ninomiya, Nobuhisa Ishikawa, Koji Inoue, et al.
Therapeutic Advances in Medical Oncology|December 26, 2022
A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study): primary analysisHisashi Tanaka, Shigeru Tanzawa, Toshihiro Misumi, et al.
Pageof 2